Edwards Lifesciences Corp has experienced a series of ups and downs, captured in its recent stock performance, which has notably underperformed when compared to its competitors. Despite this, the company has reported robust Q4 and full-year 2023 results, and with a 23% decline in stock price last year, the recent gains might placate its institutional shareholders, which own a significant 83-84% stake in the company. Also, Edwards Lifesciences is focusing intensely on its core heart business and is spinning off its critical care unit, which Becton Dickinson (BD) will acquire for $4.2 billion. This deal signifies a major move towards becoming an advanced monitoring technology leader. The quarterly results showed mixed figures with Q2 2024 earnings missing the mark and subsequent downward adjustments in price targets. Key purchases, such as Innovalve, as well as expansions, namely acquisitions of JenaValve and Endotronix, are expected to boost the company’s TMVR solutions. However, a key challenge for Edwards Lifesciences is reliance on International sales, and a slowdown in its TAVR business.
Edwards Lifesciences Corp EW News Analytics from Thu, 07 Dec 2023 08:00:00 GMT to Sat, 03 Aug 2024 21:57:23 GMT -
Rating -3
- Innovation 4
- Information 5
- Rumor -2
